



PRESS RELEASE OCTOBER 21<sup>st</sup>, 2011

## MOBERG DERMA NOMINATION COMMITTEE APPOINTED

**In accordance with the decision taken at Moberg Derma's Annual General Meeting 2011 the Chairman of the Board has contacted the largest shareholders of the company to appoint a Nomination Committee before the Annual General Meeting 2012.**

The appointed Nomination Committee consists of:

Mats Pettersson, Chairman of the Board  
Per-Olof Edin, Östersjöstiftelsen  
Conny Bogentoft, SIX SIS AG  
Oscar Ahlgren, Mohammed Al Amoudi

Per-Olof Edin has been appointed Chairman of the Nomination Committee.

Moberg Derma shareholders are encouraged to send in proposals to the Nomination Committee on or before 31 December 2011, to [info@mobergderma.se](mailto:info@mobergderma.se).

**For further information, please contact:**

Peter Wolpert, President and CEO of Moberg Derma  
Telephone: +46 8 522 307 00  
Mobile: +46 70- 735 71 35  
E-mail: [peter.wolpert@mobergderma.se](mailto:peter.wolpert@mobergderma.se)

Magnus Persson, IR  
Mobile: +46 73-355 26 01  
E-mail: [magnus.persson@mobergderma.se](mailto:magnus.persson@mobergderma.se)

**About Moberg Derma**

Moberg Derma AB (publ), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company's products are based on proven compounds, which reduce time to market, development costs and risk. Moberg Derma's first product Nalox<sup>®</sup>/Emtrix<sup>®</sup> - for nail disorders - became the Nordic market leader directly after launch in autumn 2010 and international launch is ongoing. The portfolio includes approved and launched products to projects in the preclinical and clinical phase. The company began operations at the Karolinska Institute in Stockholm in 2006. The share of Moberg Derma is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: [www.mobergderma.com](http://www.mobergderma.com)